Search Results

Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued a letter to shareholders from Jose Vieira, CEO of Procaps.

Procaps Group, S.A. announced its financial results for the three months ended September 30, 2023 and the nine months ended September 30, 2023.

Procaps Group, a leading integrated LatAm healthcare and pharmaceutical services company, announced that it is conducting a process to explore strategic alternatives to maximize shareholder value.

Procaps Group announced that it has received a letter from the Nasdaq Stock Market, dated May 16, 2024, notifying the Company that it is not in compliance with the requirements for continued listing set forth in Nasdaq Listing Rule 5250 because it did not timely file its annual report on Form 20-F for the year ended December 31, 2023.

Procaps Group announced a strategic leadership transition as Ruben Minski, founder and CEO of Procaps prepares to transition from the role of Chief Executive Officer to focus exclusively on his role as Executive Chairman of the Board, and the appointment of Jose Antonio Vieira as the new Chief Executive Officer of Procaps Group.

Procaps Group, a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced the appointment of one new member to its Board of Directors.

Procaps Group, S.A., a leading integrated LatAm healthcare and pharmaceutical services company, announced that it has entered into an agreement with BDR Pharmaceuticals International Pvt. Limited for 27 oncology molecules for Latin America, including 20 TKIs.

Procaps Group, S.A., a leading integrated international healthcare and pharmaceutical services company, announced its financial results for the three months ended June 30, 2023 and the six months ended June 30, 2023.